Navigation Links
Infinata’s BioPharm Insight to Offer Exclusive Preview of 2013 Key Reports at the BIO International Conference and Partnerships in Clinical Trials

Norwood, MA (PRWEB) April 19, 2013

BioPharm Insight(TM), Infinata’s flagship intelligence solution for the global biopharmaceutical community, will be active participants the upcoming BIO International Conference and the 22nd Annual Partnerships in Clinical Trials conference this month, with an exclusive preview of key reports for 2013:

May Catalyst Monitor highlights significant upcoming catalysts, including:

  • Difficulties AVEO’s tivozanib might face if approved for advanced renal cell carcinoma
  • Whether Delcath’s Melblez progression-free survival data is sufficient enough for US approval
  • Nektar Therapeutic’s NKTR-118 in opioid-induced constipation

CRO/CMO Quarterly Report analyzes clinical study activity across the globe. Included within the report is clinical activity by region and country, therapeutic area, and site activity. One trend reported was a drop in the number of clinical trials and the number of enrolled patients in the first quarter of 2013 compared to the first quarter of 2012.

Orphan Drugs Report discusses the top global trends within the orphan disease space, including forward-looking editorial coverage on:

  • Amicus’ and BioMarin’s drug candidates for Pompe disease
  • Xenikos co-development discussions for orphan GVHD drug
  • Case-by-case reimbursement for Aegerion’s Juxtapid and Sanofi/Isis’ Kynamro

Post-ACC Report summarizing our editorial team’s coverage of the American College of Cardiology Meeting. Significant industry topics include:

  • Portola’s betrixaban faces comparison to past failures and possibility for safety issues in ongoing Phase III APEX study
  • Experts views on Bayer and J&J’s plans to pursue anticoagulant Xarelto in coronary artery disease and chronic heart failure
  • Merck’s vorapaxar approval chances in myocardial infarction

To learn how BioPharm Insight can help you find new business opportunities, stop by booth #210 at Partnerships in Clinical Trials for an onsite demo or start your free trial today. Gain access to all the data, analytics and intelligence mentioned in this news release.

About BioPharm Insight
BioPharm Insight is the definitive guide to the global biopharma community. BioPharm Insight provides subscribers with an information edge by combining the most comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists months or even years before it breaks in mainstream media. To learn more, visit Follow BioPharm Insight on LinkedIn and Twitter.

About Infinata, Inc.
Infinata provides personalized technology solutions to turn information into insight. Services include a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. To learn more, visit

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Galien Foundation Appoints Kimberly Ha of Infinata’s BioPharm Insight to US Advisory Board
2. Infinata’s BioPharm Insight Gears Up for the 2013 American College of Cardiology Meeting with the Release of its Cardiovascular Diseases Report
3. Infinata’s BioPharm Insight Releases Licensing League Tables Report for 4Q12 and YE12
4. Infinata’s BioPharm Insight Signs 200th Media Partner, Inaugurates Advertising Program
5. Infinata’s BioPharm Insight™ Achieves Record Growth in 2012
6. Infinata's BioPharm Insight Global Editor Kim Ha to Moderate Panel at 3rd Annual U.S.-China Conference on Strategies for Mining Profits from Pharma Opportunities in China
7. Verified Clinical Trials (VCT) Will Co-Present With SAFE-BioPharma At Bio-IT World April 10th In Boston, MA Exploring Identity Management In eClinical Trials
8. Infinata Implements “Clear Quality” Initiative to Optimize Reliability and Usability of Data, Reports and Analysis for Biopharma and Wealth Management Solutions
9. BioPharm Insight Journalist Awarded Fellowship by Association of Health Care Journalists
10. BioPharm Insight Releases its Catalyst Monitor for April 2013
11. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... business and prospects remain fundamentally strong and highlights ... doxorubicin) recently received DSMB recommendation to continue the ... review of the final interim efficacy and safety ... Endpoint in men with heavily pretreated castration- and ...
(Date:11/25/2015)... PORTLAND, Oregon , November 25, 2015 /PRNewswire/ ... Deep Market Research Report is a professional and ... Genomics industry.      (Logo: ... basic overview of the industry including definitions, classifications, ... analysis is provided for the international markets including ...
(Date:11/24/2015)... ... , ... The United States Golf Association (USGA) today announced Dr. Bruce Clarke, ... annually since 1961, the USGA Green Section Award recognizes an individual’s distinguished service to ... Clarke, of Iselin, N.J., is an extension specialist of turfgrass pathology in the department ...
(Date:11/24/2015)... /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the quarter ended September 30, 2015. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of ... only value enriching for this clinical program, but ...
Breaking Biology Technology:
(Date:11/17/2015)... -- Vigilant Solutions announces today that Mr. Dick W. ... --> --> Mr. Boyce ... at TPG Capital, one of the largest global investment ... revenue.  He founded and led TPG,s Operating Group, which ... 1997 to 2013.  In his first role, he served ...
(Date:11/12/2015)... -- A golden retriever that stayed healthy despite having the ... a new lead for treating this muscle-wasting disorder, report ... MIT and Harvard and the University of São Paolo ... Cell, pinpoints a protective gene that boosts muscle ... Boston Children,s lab of Lou Kunkel , PhD, ...
(Date:11/11/2015)... Minn. , Nov. 11, 2015   MedNet Solutions ... entire spectrum of clinical research, is pleased to announce that ... in Clinical Trials (PCT) event, to be held November ... be able to view live demonstrations of iMedNet ... and learn how iMedNet has been able to ...
Breaking Biology News(10 mins):